MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558421 | Name: BI-69A11

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BI-69A11 is a dual inhibitor of AKT and NFkB pathway. It enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.

Chemical Structure

BI-69A11
BI-69A11
CAS#1233322-09-2

Theoretical Analysis

MedKoo Cat#: 558421

Name: BI-69A11

CAS#: 1233322-09-2

Chemical Formula: C25H16ClN3O2

Exact Mass: 425.0900

Molecular Weight: 425.87

Elemental Analysis: C, 70.51; H, 3.79; Cl, 8.32; N, 9.87; O, 7.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BI-69A11; BI 69A11; BI69A11;
IUPAC/Chemical Name
(E)-3-(3-(1H-benzo[d]imidazol-2-yl) acryloyl)-6-chloro-4-phenylquinolin-2(1H)-one
InChi Key
SBOKKVUBLNZTCT-OUKQBFOZSA-N
InChi Code
InChI=1S/C25H16ClN3O2/c26-16-10-11-18-17(14-16)23(15-6-2-1-3-7-15)24(25(31)29-18)21(30)12-13-22-27-19-8-4-5-9-20(19)28-22/h1-14H,(H,27,28)(H,29,31)/b13-12+
SMILES Code
O=C1NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=C1C(/C=C/C4=NC5=CC=CC=C5N4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 425.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pal I, Sarkar S, Rajput S, Dey KK, Chakraborty S, Dash R, Das SK, Sarkar D, Barile E, De SK, Pellecchia M, Fisher PB, Mandal M. BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt. Br J Cancer. 2014 Jul 8;111(1):101-11. doi: 10.1038/bjc.2014.227. Epub 2014 Jun 3. PubMed PMID: 24892445; PubMed Central PMCID: PMC4090725. 2: Pal I, Parida S, Prashanth Kumar BN, Banik P, Kumar Dey K, Chakraborty S, Bhutia SK, Mandal M. Blockade of autophagy enhances proapoptotic potential of BI-69A11, a novel Akt inhibitor, in colon carcinoma. Eur J Pharmacol. 2015 Oct 15;765:217-27. doi: 10.1016/j.ejphar.2015.08.039. Epub 2015 Aug 22. PubMed PMID: 26306675. 3: Feng Y, Lau E, Scortegagna M, Ruller C, De SK, Barile E, Krajewski S, Aza-Blanc P, Williams R, Pinkerton AB, Jackson M, Chin L, Pellecchia M, Bosenberg M, Ronai ZA. Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11. Pigment Cell Melanoma Res. 2013 Jan;26(1):136-42. doi: 10.1111/pcmr.12033. Epub 2012 Nov 2. PubMed PMID: 23035722; PubMed Central PMCID: PMC3632643. 4: Pal I, Dey KK, Chaurasia M, Parida S, Das S, Rajesh Y, Sharma K, Chowdhury T, Mandal M. Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour Biol. 2016 May;37(5):6389-402. doi: 10.1007/s13277-015-4399-6. Epub 2015 Dec 2. PubMed PMID: 26631035. 5: Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Heryln M, Krajewski S, Pellecchia M, Ronai ZA, Chiang GG. Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell Melanoma Res. 2011 Aug;24(4):703-13. doi: 10.1111/j.1755-148X.2011.00867.x. Epub 2011 Jun 6. PubMed PMID: 21592316; PubMed Central PMCID: PMC3158838. 6: Gaitonde S, De SK, Tcherpakov M, Dewing A, Yuan H, Riel-Mehan M, Krajewski S, Robertson G, Pellecchia M, Ronai Z. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res. 2009 Apr;22(2):187-95. doi: 10.1111/j.1755-148X.2009.00544.x. Epub 2009 Jan 17. PubMed PMID: 19175524; PubMed Central PMCID: PMC2860277. 7: Barile E, De SK, Feng Y, Chen V, Yang L, Ronai Z, Pellecchia M. Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma. Chem Biol Drug Des. 2013 Nov;82(5):520-533. doi: 10.1111/cbdd.12177. Epub 2013 Sep 25. PubMed PMID: 23790042; PubMed Central PMCID: PMC3966491.